A single issue mutation, V6A, released in the molecule tremendously improved the toxicity profile and diminished VLS compared to the WT molecule [76]. Further scientific studies and scientific trials will probably be vital to ascertain if this modified construct has enhanced protection and efficacy in humans.IL-18 might be another cytokine involved